Premium
Annovis Bio Inc (ANVS)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also deve... Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.518134715026 | 1.93 | 2.17 | 1.89 | 1202173 | 1.95285817 | CS |
| 4 | 0.23 | 13.4502923977 | 1.71 | 2.17 | 1.645 | 947684 | 1.82186557 | CS |
| 12 | 0.17 | 9.60451977401 | 1.77 | 2.4705 | 1.645 | 1110702 | 1.95653321 | CS |
| 26 | -2.03 | -51.1335012594 | 3.97 | 4.017 | 1.5407 | 862781 | 2.09702639 | CS |
| 52 | -0.65 | -25.0965250965 | 2.59 | 5.5 | 1.5407 | 969695 | 2.63313584 | CS |
| 156 | -11.64 | -85.7142857143 | 13.58 | 22.49 | 1.11 | 662210 | 5.55612892 | CS |
| 260 | -111.06 | -98.2831858407 | 113 | 132 | 1.11 | 455767 | 9.69472538 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
